High‐sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients’ sera
Identifieur interne : 001468 ( Main/Exploration ); précédent : 001467; suivant : 001469High‐sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients’ sera
Auteurs : Danilo Ritz [Suisse] ; Andreas Gloger [Suisse] ; Benjamin Weide [Allemagne] ; Claus Garbe [Allemagne] ; Dario Neri [Suisse] ; Tim Fugmann [Suisse]Source :
- PROTEOMICS [ 1615-9853 ] ; 2016-05.
Abstract
The characterization of peptides bound to human leukocyte antigen (HLA) class I is of fundamental importance for understanding CD8+ T cell‐driven immunological processes and for the development of immunomodulatory therapeutic strategies. However, until now, the mass spectrometric analysis of HLA‐bound peptides has typically required billions of cells, still resulting in relatively few high‐confidence peptide identifications. Capitalizing on the recent developments in mass spectrometry and bioinformatics, we have implemented a methodology for the efficient recovery of acid‐eluted HLA peptides after purification with the pan‐reactive antibody W6/32 and have identified a total of 27 862 unique peptides with high confidence (1% false discovery rate) from five human cancer cell lines. More than 93% of the identified peptides were eight to 11 amino acids in length and contained signatures that were in excellent agreement with published HLA binding motifs. Furthermore, by purifying soluble HLA class I complexes (sHLA) from sera of melanoma patients, up to 972 high‐confidence peptides could be identified, including melanoma‐associated antigens already described in the literature. Knowledge of the HLA class I peptidome should facilitate multiplex tetramer technology‐based characterization of T cells, and allow the development of patient selection, stratification and immunomodulatory therapeutic strategies.
Url:
DOI: 10.1002/pmic.201500445
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000484
- to stream Istex, to step Curation: 000484
- to stream Istex, to step Checkpoint: 000052
- to stream Main, to step Merge: 001473
- to stream Main, to step Curation: 001468
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">High‐sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients’ sera</title>
<author><name sortKey="Ritz, Danilo" sort="Ritz, Danilo" uniqKey="Ritz D" first="Danilo" last="Ritz">Danilo Ritz</name>
</author>
<author><name sortKey="Gloger, Andreas" sort="Gloger, Andreas" uniqKey="Gloger A" first="Andreas" last="Gloger">Andreas Gloger</name>
</author>
<author><name sortKey="Weide, Benjamin" sort="Weide, Benjamin" uniqKey="Weide B" first="Benjamin" last="Weide">Benjamin Weide</name>
</author>
<author><name sortKey="Garbe, Claus" sort="Garbe, Claus" uniqKey="Garbe C" first="Claus" last="Garbe">Claus Garbe</name>
</author>
<author><name sortKey="Neri, Dario" sort="Neri, Dario" uniqKey="Neri D" first="Dario" last="Neri">Dario Neri</name>
</author>
<author><name sortKey="Fugmann, Tim" sort="Fugmann, Tim" uniqKey="Fugmann T" first="Tim" last="Fugmann">Tim Fugmann</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:850105847CD61D190215F328FDED95B3514E1288</idno>
<date when="2016" year="2016">2016</date>
<idno type="doi">10.1002/pmic.201500445</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-MBFCZLJT-1/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000484</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000484</idno>
<idno type="wicri:Area/Istex/Curation">000484</idno>
<idno type="wicri:Area/Istex/Checkpoint">000052</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000052</idno>
<idno type="wicri:doubleKey">1615-9853:2016:Ritz D:high:sensitivity:hla</idno>
<idno type="wicri:Area/Main/Merge">001473</idno>
<idno type="wicri:Area/Main/Curation">001468</idno>
<idno type="wicri:Area/Main/Exploration">001468</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">High‐sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients’ sera</title>
<author><name sortKey="Ritz, Danilo" sort="Ritz, Danilo" uniqKey="Ritz D" first="Danilo" last="Ritz">Danilo Ritz</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>Philochem AG, Otelfingen</wicri:regionArea>
<wicri:noRegion>Otelfingen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gloger, Andreas" sort="Gloger, Andreas" uniqKey="Gloger A" first="Andreas" last="Gloger">Andreas Gloger</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>Institute of Pharmaceutical Sciences, ETH Zurich, Zurich</wicri:regionArea>
<wicri:noRegion>Zurich</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Weide, Benjamin" sort="Weide, Benjamin" uniqKey="Weide B" first="Benjamin" last="Weide">Benjamin Weide</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, Division of Dermatologic Oncology, Eberhard‐Karls‐University, Tuebingen</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Tübingen</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Immunology, Eberhard‐Karls‐University, Tuebingen</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Tübingen</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garbe, Claus" sort="Garbe, Claus" uniqKey="Garbe C" first="Claus" last="Garbe">Claus Garbe</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, Division of Dermatologic Oncology, Eberhard‐Karls‐University, Tuebingen</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Tübingen</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Neri, Dario" sort="Neri, Dario" uniqKey="Neri D" first="Dario" last="Neri">Dario Neri</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>Institute of Pharmaceutical Sciences, ETH Zurich, Zurich</wicri:regionArea>
<wicri:noRegion>Zurich</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">Suisse</country>
<wicri:regionArea>: Professor Dr. Dario Neri, Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir‐Prelog‐Weg 1–5/10, HCI G 392.4, 8093 Zurich</wicri:regionArea>
<wicri:noRegion>8093 Zurich</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Suisse</country>
</affiliation>
</author>
<author><name sortKey="Fugmann, Tim" sort="Fugmann, Tim" uniqKey="Fugmann T" first="Tim" last="Fugmann">Tim Fugmann</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>Philochem AG, Otelfingen</wicri:regionArea>
<wicri:noRegion>Otelfingen</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">PROTEOMICS</title>
<title level="j" type="alt">PROTEOMICS</title>
<idno type="ISSN">1615-9853</idno>
<idno type="eISSN">1615-9861</idno>
<imprint><biblScope unit="vol">16</biblScope>
<biblScope unit="issue">10</biblScope>
<biblScope unit="page" from="1570">1570</biblScope>
<biblScope unit="page" to="1580">1580</biblScope>
<biblScope unit="page-count">11</biblScope>
<date type="published" when="2016-05">2016-05</date>
</imprint>
<idno type="ISSN">1615-9853</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1615-9853</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">The characterization of peptides bound to human leukocyte antigen (HLA) class I is of fundamental importance for understanding CD8+ T cell‐driven immunological processes and for the development of immunomodulatory therapeutic strategies. However, until now, the mass spectrometric analysis of HLA‐bound peptides has typically required billions of cells, still resulting in relatively few high‐confidence peptide identifications. Capitalizing on the recent developments in mass spectrometry and bioinformatics, we have implemented a methodology for the efficient recovery of acid‐eluted HLA peptides after purification with the pan‐reactive antibody W6/32 and have identified a total of 27 862 unique peptides with high confidence (1% false discovery rate) from five human cancer cell lines. More than 93% of the identified peptides were eight to 11 amino acids in length and contained signatures that were in excellent agreement with published HLA binding motifs. Furthermore, by purifying soluble HLA class I complexes (sHLA) from sera of melanoma patients, up to 972 high‐confidence peptides could be identified, including melanoma‐associated antigens already described in the literature. Knowledge of the HLA class I peptidome should facilitate multiplex tetramer technology‐based characterization of T cells, and allow the development of patient selection, stratification and immunomodulatory therapeutic strategies.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Suisse</li>
</country>
<region><li>Bade-Wurtemberg</li>
<li>District de Tübingen</li>
</region>
<settlement><li>Tübingen</li>
</settlement>
</list>
<tree><country name="Suisse"><noRegion><name sortKey="Ritz, Danilo" sort="Ritz, Danilo" uniqKey="Ritz D" first="Danilo" last="Ritz">Danilo Ritz</name>
</noRegion>
<name sortKey="Fugmann, Tim" sort="Fugmann, Tim" uniqKey="Fugmann T" first="Tim" last="Fugmann">Tim Fugmann</name>
<name sortKey="Gloger, Andreas" sort="Gloger, Andreas" uniqKey="Gloger A" first="Andreas" last="Gloger">Andreas Gloger</name>
<name sortKey="Neri, Dario" sort="Neri, Dario" uniqKey="Neri D" first="Dario" last="Neri">Dario Neri</name>
<name sortKey="Neri, Dario" sort="Neri, Dario" uniqKey="Neri D" first="Dario" last="Neri">Dario Neri</name>
<name sortKey="Neri, Dario" sort="Neri, Dario" uniqKey="Neri D" first="Dario" last="Neri">Dario Neri</name>
</country>
<country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Weide, Benjamin" sort="Weide, Benjamin" uniqKey="Weide B" first="Benjamin" last="Weide">Benjamin Weide</name>
</region>
<name sortKey="Garbe, Claus" sort="Garbe, Claus" uniqKey="Garbe C" first="Claus" last="Garbe">Claus Garbe</name>
<name sortKey="Weide, Benjamin" sort="Weide, Benjamin" uniqKey="Weide B" first="Benjamin" last="Weide">Benjamin Weide</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001468 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001468 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:850105847CD61D190215F328FDED95B3514E1288 |texte= High‐sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients’ sera }}
This area was generated with Dilib version V0.6.33. |